Novi GLP-1 Weight Loss at a Glance
In 2026, GLP-1 weight loss treatment has become one of the most searched topics in prescription health — and with it, questions about what telehealth access actually looks like, how compounded semaglutide and compounded tirzepatide are positioned within prescription care, and how platforms like Novi structure their programs for eligible adults.
Novi GLP-1 Weight Loss is a telehealth platform built around clinician-reviewed access to prescription weight management medication. The program is structured around an online intake process, licensed provider evaluation, prescription access when medically appropriate, monthly medication shipment, and ongoing clinical support — reducing the need for in-person visits or pharmacy pickup when treatment is prescribed.
50,000+ patients have started a GLP-1 journey through Novi. The platform lists compounded semaglutide from $133 per month and compounded tirzepatide from $166 per month as its primary treatment options for eligible adults following licensed provider review. Pricing, availability, and offers are subject to change — current terms are listed at joinnovi.com.
How Novi Structures Its GLP-1 Telehealth Program
Novi's GLP-1 telehealth program is built around three stages: intake, clinician evaluation, and prescription fulfillment — followed by ongoing monthly support.
- Intake: The process starts with a 3-minute online pre-approval quiz.
- Clinician Evaluation: Patients who meet initial eligibility criteria move on to a consultation with a US-licensed clinician — a physician or nurse practitioner — who reviews their health history and independently determines whether a GLP-1 prescription is medically appropriate. A prescription is not guaranteed.
- Prescription & Fulfillment: When a prescription is issued, Novi ships a 4-week medication supply with needed supplies, via free 2-day shipping.
- Ongoing Support: Each monthly renewal includes another 4-week supply. Patients have ongoing access to Novi's clinical team for dose adjustments, questions, and side-effect support — included in the monthly price. Coaching support is also included at no additional cost.
Novi's provider team includes US-licensed physicians and nurse practitioners with board certifications spanning emergency medicine, internal medicine, and family practice.
What Semaglutide and Tirzepatide Are Designed to Do
GLP-1 receptor agonists are a class of prescription medications that work by mimicking the GLP-1 hormone, which the body naturally releases after eating. These medications are designed to work with appetite, fullness, and metabolic signaling pathways that may influence food intake under clinician supervision.
Semaglutide and tirzepatide are FDA-recognized active ingredients used in several branded prescription weight loss and diabetes medications. Novi offers compounded versions of these active ingredients, prepared by licensed US compounding pharmacies. Novi is not affiliated with the manufacturers of any branded medications containing these active ingredients.
Clinical studies of the active ingredients in GLP-1 medications have reported substantial weight-loss outcomes in studied populations — with some trials reporting average body weight reductions in the range of 15% to 24% over extended treatment periods. These figures reflect results from clinical trials of the active ingredients, not from Novi's program specifically. Individual results vary, and no specific outcome is guaranteed. A licensed clinician evaluates each patient's circumstances individually before any prescription is issued.
Compounded Medication Notice
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They contain the same active ingredients as their branded counterparts but are prepared by licensed US compounding pharmacies under state and federal pharmacy law — not through the FDA's drug approval process for safety, efficacy, or manufacturing quality.
FDA policy around compounded GLP-1 medications remains highly active in 2026. The FDA has stated that semaglutide and tirzepatide do not currently appear on the 503B bulks list or the FDA drug shortage list, and the agency has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Patients considering compounded GLP-1 treatment should confirm current availability through Novi and discuss medication status, risks, and alternatives with a licensed clinician.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any prescription medication. This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the purchaser.